Asthma Clinical Trial
Official title:
A Study Evaluating the Role of Cigarette Smoking in Regulating Allergen-induced Early and Late Responses in Mild Asthmatics.
The objective of this study is to determine the effect of cigarette smoking on inflammatory
cell recruitment to the lungs after an allergen challenge, in non-smoking and currently
smoking mild asthmatic subjects.
When comparing non-smoking asthmatics to smoking asthmatics, do differential cell counts
obtained from inflammatory cells in induced sputum after allergen challenge differ?
Will differential cell counts show a decline in inflammatory cells in the induced sputum of
asthmatics who have refrained from smoking for eight weeks?
This study is a randomized, case-controlled study. The first part of the study requires
smoking and non-smoking subjects who will attend 2 study periods of 3 consecutive days
(triad). In each triad, they will be challenged with allergen or diluent by inhalation, in a
random order, and each triad is separated by a washout period. In the second part of the
study, current smokers will be invited to undergo another allergen challenge 8 weeks of
smoking cessation.
10 non-smoking adult subjects and 10 smoking adult subjects with mild atopic asthma will be
studied.
Part 1: On the first study day of the triad, subjects will undergo screening procedures,
including complete history and physical examination. Methacholine inhalation challenge and
allergen skin titration will be performed to determine the concentration of allergen
required for inhalation. Sputum will be induced for baseline measurement of airway
inflammatory cells. On the second day, subjects will inhale the allergen or diluent in
randomized order, and spirometry will be measured for the next 7 hours. Sputum will be
collected at 7 hours after challenge. On the third day, subjects will report to the lab 24
hours after allergen/diluent inhalation challenge. Sputum cells will be collected to measure
the percentage of airway inflammatory cells, including eosinophils and neutrophils. After
washout of 2-4 weeks, subjects will return to undergo diluent/allergen triad.
Part 2: Asthmatic smokers will be studied to investigate allergen-induced changes in
inflammatory cell numbers after they quit smoking for a period of 8 weeks. Asthmatic smokers
who were involved in the first part of the study will be asked if they would like to
participate in this part of the study, and they will be provided with smoking cessation
tools including nicorette gum and nicotine patches, to aid them in ceasing to smoke. At the
beginning of the study period, the same procedures that occurred in part 1 will be performed
to obtain initial baseline results- ie- history, physical examination, skin prick test,
methacholine challenge and sputum induction. Throughout the 8 week period, subjects will be
required to come in weekly to perform a carboxyhemoglobin test, to ensure that they have not
been smoking that week. At the end of the 8 week period, an allergen challenge triad will be
carried out (as was performed in Part 1 of the study). Those subjects who were not able to
comply to the smoking cessation regime will still be included in the final measurements.
We hypothesize that inflammatory cell counts will be higher in the asthmatic smokers versus
asthmatic non-smokers. We also hypothesize that subjects who quit smoking for the 8 week
period will show a decline in inflammatory cell counts indicating an improvement in lung
function.
We believe that the results of this novel study will provide greater insight into the
inflammatory response in asthmatic smokers, and will suggest appropriate therapeutic
approaches for control of asthma in smokers.
;
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|